한글목차

세계의 인공 혈액 시장 규모는 2022년 2,390만 달러, 2023년 2,610만 달러에서 예측기간 중 9.2%의 CAGR로 성장하여 2028년에는 4,050만 달러 규모로 성장할 것으로 예측됩니다.

세계의 인공 혈액 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추정과 예측, 각종 부문·지역별 상세 분석, 제품 분석, 기술·특허 동향, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.

목차

제1장 서론

제2장 요약과 하이라이트

제3장 시장 개요

• 인간 혈액의 문제
• 인공 혈액에 대한 새로운 요구
• 인공 혈액 : 감염증 위험에 대한 대처에 유용
• 인공 혈액 : 공여자 혈액 공급 부하를 경감
• 인공 혈액 : 혈액 시스템의 예기치 못한 수요에 대한 대처에 필요
• 인공 혈액제재 개발 허들
• 인공 혈액의 이상적인 특성
• 인간 혈액보다 뛰어난 인공 혈액
• 용도
• 수술
• 긴급 소생
• 단기 사용
• 인간 혈액보다 효과적인 케이스
• 종교적 신념에 의한 거부
• 인공 혈액 개발의 과제

제4장 시장 역학

• 성장 촉진요인
• 수혈 수요 증가
• 수혈에 따른 위험과 과제
• 혈액 공급 부족
• 장벽
• 낮은 제품 승인율
• 제품 수용
• 제품 가격 설정
• 기회
• COVID-19의 영향

제5장 인공 혈액 : 공급원별

• 인간 혈액에서 개발된 인공 혈액
• 동물 혈액에서 개발된 인공 혈액
• 유전자 재조합 기술을 이용해 개발된 인공 혈액
• 표면 변성 헤모글로빈
• 가교 헤모글로빈
• 중합 헤모글로빈
• 캡슐화
• 유전자 조작된 재조합 헤모글로빈
• 천연 헤모글로빈

제6장 인공 혈액 : 유형별

• 퍼플루오로카본 에멀전
• 퍼플루오로카본의 일반적인 특성
• 유제 선택
• 퍼플루오로카본 에멀전의 역사적 발전
• 제1세대 PFC
• 제2세대 PFC
• 제3세대 PFC
• 헤모글로빈 기반 산소 운반체(HBOC)
• HBOC의 일반적인 특징
• 역사적 사건 : 헤모글로빈 용액

제7장 시장 추정

• 인공 혈액의 잠재적 시장
• 인공 혈액 시장 : 공급원별
• 혈액(동물/인간)
• 합성 폴리머
• 인공 혈액 시장 : 유형별
• 헤모글로빈 기반 산소 운반체
• 퍼플루오로카본 제품
• 인공 혈액 시장 : 지역별
• 북미
• 유럽
• 신흥 시장

제8장 새로운 기술과 개발

• 개요
• 신기술
• 나노 캡슐 기술
• 줄기세포
• 혈액 대체품에 관한 기타 진행중인 연구

제9장 제품 분석

• 제품 안전성
• 제품 유효성
• 제품 원가
• 법적 영향
• 개발중인 일부 제품의 제품 분석
• Hemopure
• HemO2life
• HemoTech
• NanO2(DDFPe)
• Sanguinate
• Vidaphor
• 임상시험
• 전임상 및 초기 단계 I상의 일부 제품 설명
• ErythroMer
• Hemoglobin vesicles
• OxyVita
• OxyBridge

제10장 특허 분석

• FDA 규제
• FDA 적정 제조 기준· 보고
• 특허 분석

제11장 경쟁 정보

• 전략적 전개
• 경쟁 분석

제12장 기업 개요

• AURUM BIOSCIENCES
• ERYPHARM
• HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
• HEMARINA
• KALOCYTE INC.
• NANO SANGUIS S.A
• NUVOX PHARMA LLC.
• PROLONG PHARMACEUTICALS, LLC
• RED C BIOTECH
• VIRTECH BIO

영문목차

Highlights:

The global artificial blood market reached $23.9 million in 2022, should reach $26.1 million by 2023 and $40.5 million by 2028 with a compound annual growth rate (CAGR) of 9.2% during the forecast period of 2023-2028.

Report Scope:

The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.

Report Includes:

• 41 tables
• An overview of the global markets for artificial blood
• Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Highlights of the market potential and characterization of artificial blood market by product, application, and region
• Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
• Coverage of recent advances, emerging technologies, and developments of the industry
• Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
• Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market Overview

• Introduction
• Is There a Problem with Human Blood?
• Emerging Needs for Artificial Blood
• Artificial Blood Will Be Useful in Dealing with the Risks of Infection
• Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
• Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
• Hurdles in the Development of Artificial Blood Products
• Ideal Characteristics of Artificial Blood
• Artificial Blood Over Human Blood
• Applications
• Surgeries
• Emergency Resuscitation
• For Short-term Use
• Where More Effective Than Human Blood
• Rejections Due to Religious Beliefs
• Challenges in Artificial Blood Development

Chapter 4 Market Dynamics

• Drivers
• Increasing Demand for Blood Transfusions
• Risks and Challenges Associated with Blood Transfusions
• Shortage of Blood Supply
• Barriers
• Low Rate of Product Approvals
• Product Acceptance
• Product Pricing
• Opportunities
• Impact of COVID-19

Chapter 5 Artificial Blood by Source

• Introduction
• Artificial Blood Developed from Human Blood
• Artificial Blood Developed from Animal Blood
• Artificial Blood Developed Using Recombinant Technology
• Surface Modified Hemoglobin
• Cross-Linked Hemoglobin
• Polymerized Hemoglobin
• Encapsulation
• Genetically Engineered Recombinant Hemoglobin
• Natural Hemoglobin

Chapter 6 Artificial Blood by Type

• Introduction
• Perfluorocarbon Emulsions
• General Characteristics of Perfluorocarbons
• Emulsion Selection
• Historical Developments of Perfluorocarbon Emulsions
• First Generation of PFCs
• Second Generation of PFCs
• Third Generation of PFCs
• Hemoglobin-based Oxygen Carriers
• General Characteristics of HBOCs
• Historical Events: Hemoglobin Solutions

Chapter 7 Market Estimation

• Introduction
• Potential Market for Artificial Blood
• Artificial Blood Market, by Source
• Blood (Animal/Human)
• Synthetic Polymers
• Artificial Blood Market, by Type
• Hemoglobin-based Oxygen Carriers
• Perfluorocarbon-based Products
• Artificial Blood Market, by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Emerging Technologies and Developments

• Overview
• Emerging Technologies
• Nanocapsule Technology
• Stem Cells
• Other Ongoing Research for Blood Substitutes

Chapter 9 Product Analysis

• Introduction
• Product Safety
• Product Effectiveness
• Product Cost
• Legal Implications
• Product Analysis of Some of the Products Under Development
• Hemopure
• HemO2life
• HemoTech
• NanO2 (DDFPe)
• Sanguinate
• Vidaphor
• Clinical Trials
• Product Description of Some of the Products in Preclinical and Early Phase I Stage
• ErythroMer
• Hemoglobin vesicles
• OxyVita
• OxyBridge

Chapter 10 Patent Analysis

• Introduction
• FDA Regulation
• FDA Good Manufacturing Practices and Reporting
• Patent Analysis

Chapter 11 Competitive Intelligence

• Strategic Developments
• Competitive Analysis

Chapter 12 Company Profiles

• AURUM BIOSCIENCES
• ERYPHARM
• HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
• HEMARINA
• KALOCYTE INC.
• NANO SANGUIS S.A
• NUVOX PHARMA LLC.
• PROLONG PHARMACEUTICALS, LLC
• RED C BIOTECH
• VIRTECH BIO